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ABSTRACT 
Introduction: The immunity against cervical cancers is many unknown. Major histocompatability complex class I 
(MHC-I) with the alpha domain has binding site for Cytotoxic T cells (CD8+) to target cells. The objective of this ex-
periment is to known the expression of CD8+ and MHC-I in cervical cancer with HPV infection. Method: DNA was 
isolated from seventeen sample cervical cancer tissues frozen section. Diagnose related with HPV was made by PCR. 
Paraffin block of the tissues was cut in thoroughly cleaned cryotome and place in glass plate that covered with 
poly-elysine. The immunohistochemistry is done with monoclonal antibody again MHC-I and CD8+ with TSA-indirect 
method. The power of expression was counted the number of positive cells to express the MHC-I and CD8+ every 100 
cells per one view look. Result: The Result of this experiment show that expression of MHC-I and CD8+ in cervical 
cancer with HPV infection is in mild category (30% - 70%). Conclusion: Immunity against uterine cancer that played 
by MHC-I and CD8+ are in milt category. The experiment that related with uterine cancer immunology is suggested. 
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1. Introduction 
Cervical cancer is the most common form neoplasm in 
women. This neoplasm is found in developing state as 
leading cause of neoplasm-related deaths in women in 
the world as a whole. Now the pathogenesis of cervical 
cancer is focused to human papilloma virus (HPV) [1-3]. 
Immunity to neoplasm or cancer as a whole are decided 
by Cytotoxic T Lymphocyte cells (CD8+, CTL, Tc), 
natural killer (NK) cells and specific antibody [4-10]. 
Immunity to destroy viruses to be many ways like in-
terferon, secretory Immunoglobulin A (s-Ig A) of epithe-
lial surface, antibody dependent cellular cytotoxicity 
(ADCC), and NK-cells, and more difficult to be sure 
which one are important [8-13]. Identity of TSAs (tu-
mor-specific antigens) in experimentally induced tumors 
and their existence on human tumors remained elusive 
until the molecular basis of T lymphocyte cell recogni-
tion was understood. With realization that T lymphocyte 
cell receptors recognize peptides bound to the antigen- 
binding cleft of major histocompatability complex mole-
cules class I [4-7]. 
CD8+ is a lymphocyte that kills other cells. CD8+ rec-
ognized class I alloantigens or conventional antigens 
(e.g., viruses) associated with class I histocompatability 
molecules [5-8]. 
MHC-I molecules are integral membrane proteins 
found on all nucleated cell and platelets. The extracellu-
lar portion has three domains. The alpha-3 domain has a 
binding site for CD8+. CD8+ T lymphocytes kill target 
cells when they recognize antigen in associated with self 
MHC-I [5-8]. 
2. Material and Method 
Frozen section tissues are collected from obstetric and 
gynecologic part of doctor Muwardi Hospital Surakarta 
patient with cervical cancer from January 2001 to Janu-
ary 2002. 
DNA isolation was made by Henk Schmits method 
with some modifications [9]. Cut up to 25 mgr of tissue 
into small pieces, place in 1.5 ml a microfuge tube vol-
ume, and add 200 ul of DNA extraction buffer. Add 20 ul 
of Proteinase K stock solution, mix by vortexing, and 
incubate at 55˚C overnight. 
Diagnose related with HPV infections are made by 
Henk Schmits and/or Nigel McMillan and Nina Fowler 
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PCR-method with some modifications [9,10]. Twenty 
five ul microfuge tube Ready To Go PCR Bead (Amer-
sham Pharmacia Biotech) mixed with 2 ul HPV consen-
sus primers (MY09 and MY11) (CYBERGENE AB) and 
2 ul DNA template. PCR protocol for both amplifications 
are 94˚C for 50 seconds, 59˚C for 50 seconds, 72˚C for 
50 seconds and 4˚C soak. 
Paraffin-embedded tissue cervical cancer with HPV 
infection are cut using a thoroughly cleaned microtome 
and placed in glass plate that covered with poly-elisen. 
Immunohistochemistry stain is done with TSA-indirect 
method (NEN Life Science Products, RENAISSENCE) 
used monoclonal antibody again MHC-I (1:500) and 
CD8+ (1:500) produced by Santa Cruz. Photo micro-
scopic collected via aX100 objective lens. 
3. Result and Discussion 
From gel electrophoresis (Figure 1) can look the 450 
band of DNA L1-HPV virus. 
Neoplasm of the cervical uterine is the most common 
form neoplasm in women. This neoplasm is found in 
developing state as leading cause of neoplasm-related 
deaths in women in the world as a whole. The mortality 
rate has been estimated at 2.8 deaths per 100,000 women, 
with a total of 252 deaths reported in 1993. Now the 
pathogenesis of cervical cancer is pointed to human 
papilloma virus (HPV). HPV infection associated with 
malignancies of urogenital tract and anus and also 
thought to be related to disorder of skin and the up-
per-respiratory tract [1-3]. 
Immunity to cancer as a whole is decided by Cytotoxic 
T cells, NK-cells and specific antibody [4-10], otherwise 
to destroy viruses of human have many ways, and more 
difficult to be sure which one is important. Number ways 
are Interferon, s-Ig A of epithelial surface, antibody and 
antibody dependent cytotoxic cell (ADCC), and NK-cells 
[5-8,11-17]. Cytokines are included in the mechanism of 
immunity to cancer. 
From immunohistochemistry stain can look in Figures 
2 and 3 and Table 1 for CD8+ expression and Figures 4 
and 5 and Table 2 for MHC-I expression. 
Cytotoxic T cell (CTL, Ts, CD8+) is a T lymphocyte 
cell that kills other cells. Most CTL are CD8+; these cell 
recognize class I alloantigens or conventional antigens 
(e.g. viruses) associated with self class I histocompata- 
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Figure 1. Gel electrophoresis the 5 sample with HPV posi-
tive. The band about 450 bp long are the DNA HPV from 
L1 gene amplified (arrow). M: Marker. 
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Figure 2. Immunohistochemistry staining of CD8+. The 
yellow-dark show that the CD8+ (black arrow) are ex-
pressed in this tissue with cervical cancer. 
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Figure 3. Expression of CD8+ from 10 sample cervical can-
cer with HPV infection. 
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Figure 4. Immunohistochemistry staining of MHC-I. The 
yellow-dark show that the MHC-I (black arrow) are ex-
pressed in this tissue with cervical cancer. 
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Figure 5. Expression of MHC-I from 10 sample cervical 
cancer with HPV infection. 
 
bility molecule. Some CTL are CD4+; these cells recog-
nize antigens associated with class II alloantigens or self 
class II histocompatability molecule. The mechanism of 
killing has been studied in detail with CD8+ T lympho-
cytes. Once a cytotoxic T lymphocyte has recognized 
antigen, it binds to the target cell and kills it within a few 
hours. The mechanism of taget killing is not well under-
stood and appears to include release of trypsin-like serine 
proteases, and cytotoxic lymphokine (e.g. perforin) [5-8, 
11-19]. 
Genetic loci involved in the rejection of foreign tissue 
or non-self-forming region known as MHC. Structure is 
highly polymorphic cell surface that are involved in the  
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Table 1. Expression of CD8+ (in percent) from 10 sample 
cervical cancer with HPV infection. 
No. of sample CD8+ (%) 
1. 40 
2. 70 
3. 40 
4. 30* 
5. 50 
6. 60 
7. 50 
8. 50 
9. 40 
10. 40 
Mean 47 
Percentage is got from cells positif/100 cells/one view look 5% - 30%: light 
expression category (*); 31% - 70%: mild expression category; 71% - 100%: 
hard expression category. 
 
Table 2. Expression of MHC-I (in percent) from 10 sample 
cervical cancer with HPV infection. 
No. of sample MHC-I (%) 
1. 40 
2. 70 
3. 50 
4. 60 
5. 50 
6. 30* 
7. 70 
8. 50 
9. 70 
10. 70 
Mean 57 
Percentage is got from cells positif/100 cells/one view look 5% - 30%: light 
expression category (*); 31% - 70%: mild expression category; 71% - 100%: 
hard expression category. 
 
rejection, which is called MHC antigen, which was ini-
tially characterized by alloantibodies produced in one 
strain of inbred mice immunized with cells from other 
types only differ in the MHC. The same technique is 
used to determine the human MHC, which is known as 
antigen (HLA) system of human leukocytes. Three 
classes have been identified as encoded in murine and 
human MHCs. MHC-I consists of a glycosylated heavy 
chain (45 kDa) non-covalent assosiated with microglobu-
line beta-2 (12 kDa) polypeptide that is also found in the 
serum-free [12-14,16]. MHC-I molecules are integral 
membrane proteins found in all nucleated cells and 
platelet. The alpha-3 domain has a binding site for Cyto-
toxic T cells. Cytotoxic T cells kill target cells when they 
recognize antigen in association with self MHC-I mole-
cules [5-8,14,20-25]. 
4. Conclution 
The result of this experiment shows that expression of 
CD8+ and MHC-I in cervical cancer with HPV infection 
are in mild category (30% - 70%). 
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